JP2012095731A - Bioabsorbable medical material - Google Patents
Bioabsorbable medical material Download PDFInfo
- Publication number
- JP2012095731A JP2012095731A JP2010244193A JP2010244193A JP2012095731A JP 2012095731 A JP2012095731 A JP 2012095731A JP 2010244193 A JP2010244193 A JP 2010244193A JP 2010244193 A JP2010244193 A JP 2010244193A JP 2012095731 A JP2012095731 A JP 2012095731A
- Authority
- JP
- Japan
- Prior art keywords
- bioabsorbable
- sheet
- layer
- gelatin
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012567 medical material Substances 0.000 title claims abstract description 36
- 239000012779 reinforcing material Substances 0.000 claims abstract description 13
- 229920000159 gelatin Polymers 0.000 claims description 64
- 239000008273 gelatin Substances 0.000 claims description 63
- 108010010803 Gelatin Proteins 0.000 claims description 62
- 235000019322 gelatine Nutrition 0.000 claims description 62
- 235000011852 gelatine desserts Nutrition 0.000 claims description 62
- 108010035532 Collagen Proteins 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 229920005615 natural polymer Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 74
- 230000000694 effects Effects 0.000 abstract description 20
- 230000023597 hemostasis Effects 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 12
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 108
- 210000001519 tissue Anatomy 0.000 description 50
- 206010052428 Wound Diseases 0.000 description 44
- 208000027418 Wounds and injury Diseases 0.000 description 44
- 239000007864 aqueous solution Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 108010025899 gelatin film Proteins 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 230000001070 adhesive effect Effects 0.000 description 14
- 239000000853 adhesive Substances 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000008215 water for injection Substances 0.000 description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 10
- 229920002674 hyaluronan Polymers 0.000 description 10
- 229960003160 hyaluronic acid Drugs 0.000 description 10
- 229920003023 plastic Polymers 0.000 description 10
- 239000004033 plastic Substances 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 229920000954 Polyglycolide Polymers 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 7
- 230000002439 hemostatic effect Effects 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010034203 Pectus Carinatum Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 238000005187 foaming Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000002674 endoscopic surgery Methods 0.000 description 2
- 238000013210 evaluation model Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
本発明は、生体内の組織に密着して創傷部における止血、被覆、閉鎖の効果の役目を果たすとともに、創傷部と周囲組織との癒着を防止する効果を有する、フィルム層と多孔質層からなる生体吸収性医療材料に関する。 The present invention provides a film layer and a porous layer that are in close contact with a tissue in a living body and play a role of hemostasis, covering and closing in a wound part, and have an effect of preventing adhesion between the wound part and surrounding tissue. It relates to a bioabsorbable medical material.
生体組織に創傷ができると生体組織から出血する。一時的に止血しても、不完全なままに放置されているとさらなる出血を引き起こすこととなり好ましくない。また、創傷部の生体組織から体液などが漏れるため、創傷部を何らかの手段で閉鎖することが必要になる。さらに、創傷部が大きい場合にはシート状材料などで創傷部を被覆しなければ、周囲から細胞や生体組織が侵入して創傷部と周囲の正常組織との間に癒着が発生し、創傷部の治癒を阻害するだけでなく種々の合併症が発生する危険性がある。 When a living tissue is wounded, bleeding occurs from the living tissue. Even if hemostasis is temporarily stopped, if it is left incomplete, it may cause further bleeding, which is not preferable. Moreover, since body fluid etc. leak from the biological tissue of a wound part, it is necessary to close a wound part by some means. Furthermore, when the wound is large, if the wound is not covered with a sheet-like material, cells and living tissues enter from the surroundings, and adhesion occurs between the wound and the surrounding normal tissue. There is a risk that various complications may occur as well as inhibiting the healing.
このような理由から、外科手術においては創傷部の止血材、被覆材、閉鎖材、癒着防止材など種々のシート状の医療材料が使用されている。よく知られた例としては、コラーゲンフリースの片面にフィブリノーゲンとトロンビンを付着したシート状の止血材料(商品名タココンブ)がある。癒着防止を目的とした材料としては、ヒアルロン酸とカルボキシメチルセルロースからなるフィルム状材料(商品名セプラフィルム)、酸化再生セルロースからなる布状材料(商品名インターシード)、ゼラチンフィルムからなる材料(特許文献1、2)などがある。また、創傷部の被覆を目的とした医療材料としては、ポリグリコリドの不織布(商品名ネオベール)などがある。これらの材料はいずれも生体吸収性であり、かつ、平面状材料である。 For these reasons, various sheet-like medical materials such as a hemostatic material, a covering material, a closing material, and an anti-adhesion material for wounds are used in surgery. A well-known example is a sheet-like hemostatic material (trade name Taco Kombu) in which fibrinogen and thrombin are attached to one side of a collagen fleece. Materials intended to prevent adhesion include film-like materials made of hyaluronic acid and carboxymethyl cellulose (trade name Sepra film), cloth-like materials made of oxidized regenerated cellulose (trade name Interseed), materials made of gelatin film (patent document) 1, 2). Moreover, as a medical material aiming at the covering of a wound part, there exists a polyglycolide nonwoven fabric (brand name Neobale) etc. All of these materials are bioabsorbable and are planar materials.
これらの材料は創傷部に密着し、容易に移動しないことが必要である。例えば、コラーゲンフリースの片面にフィブリノーゲンとトロンビンを付着したシート状材料は、フィブリノーゲンとトロンビンの接着効果によって生体組織に密着する。ヒアルロン酸とカルボキシメチルセルロースからなるフィルム状材料にはこのような接着効果はないが、生体組織に接触させると物理的に密着する。ポリグリコール酸製不織布にはこのような接着効果や密着性がないために、フィブリン糊などの接着剤を用いて生体組織に密着、固定させる必要がある。 These materials need to adhere to the wound and do not move easily. For example, a sheet-like material in which fibrinogen and thrombin are attached to one side of a collagen fleece adheres to a living tissue due to the adhesive effect of fibrinogen and thrombin. A film-like material composed of hyaluronic acid and carboxymethylcellulose does not have such an adhesive effect, but physically adheres when brought into contact with living tissue. Since the polyglycolic acid non-woven fabric does not have such an adhesive effect and adhesion, it is necessary to adhere and fix to the living tissue using an adhesive such as fibrin glue.
これらの吸収性医療材料は外科手術の成績向上に大いに貢献しているが、一方で欠点も指摘されている。例えば、ヒアルロン酸とカルボキシメチルセルロースからなるフィルム状材料の生体組織への密着効果は十分でなく、しばしば、創傷部から材料が移動してしまい、その結果として癒着を起こしてしまうことがあった。さらに、水分で濡れると材料が破れやすく、そのために材料の位置を修正するための移動ができないという欠点があった。コラーゲンフリースの片面にフィブリノーゲンとトロンビンを付着したシート状材料は、材料の伸展度が低いために生体組織に密着しにくく、そのために止血効果が不十分となる場合がある。ポリグリコリド製不織布は、接着剤を使用しなければ生体組織表面に密着、固定させることができないという問題があった(特許文献3、4)。 Although these absorbable medical materials have greatly contributed to the improvement of surgical performance, on the other hand, drawbacks have also been pointed out. For example, the adhesion of a film-like material composed of hyaluronic acid and carboxymethyl cellulose to a living tissue is not sufficient, and the material often moves from the wound part, resulting in adhesion. Furthermore, there is a drawback in that the material is easily broken when wetted with moisture, and therefore movement for correcting the position of the material cannot be performed. A sheet-like material having fibrinogen and thrombin attached to one side of a collagen fleece is difficult to adhere to a living tissue due to the low degree of extension of the material, and thus the hemostatic effect may be insufficient. The non-woven fabric made of polyglycolide has a problem that it cannot be adhered and fixed to the surface of a living tissue unless an adhesive is used (Patent Documents 3 and 4).
生体組織の創傷部に密着することが可能であり、かつ取り扱い性に優れ、止血、被覆、閉鎖、癒着防止の効果を有するとともに創傷部の治癒を促進させることができる生体吸収性医療材料を提供することである。 Provided is a bioabsorbable medical material that is capable of adhering to a wound portion of a living tissue, has excellent handleability, has an effect of preventing hemostasis, covering, closing, and adhesion, and can promote healing of the wound portion. It is to be.
本願発明者らは、これらの問題を解決するために鋭意研究を重ねた結果、生体吸収性医療材料が生体組織表面上に存在する少量の水分と接触したときにヒドロゲル状になることによって、良好な密着性を生じることを見出した。すなわち、生体吸収性医療材料の生体組織と接触する面に少量の水分によってヒドロゲル状になる多孔質層が存在するような材料を設計した。一方で、反対面には親水面のフィルム層を配し、周囲組織との癒着を防止する効果を有するように材料設計を行った。このように、多孔質層とフィルム層からなる二層構造を有する生体吸収性医療材料を用いることによって、創傷部に密着して止血、被覆、閉鎖する効果を発揮し、創傷部の治癒を促進し、さらには創傷部と周囲組織との癒着を防止することができるという、これまでの医療材料にはない優れた効果が得られることを見いだした。また、多孔質層とフィルム層からなる二層構造であるだけでなく、薄いシート状(二層シート)とすることによって、材料に柔軟性を与えることができ組織への密着性が高まり、一方では材料の強度が向上することによって壊れにくいという取り扱いに優れた材料となることを見いだした。また、補強材料を複合化させた三層シート構造とすることによって、さらに壊れにくく取り扱い性に優れた材料とすることに成功した。 The inventors of the present invention have conducted extensive research to solve these problems, and as a result, when the bioabsorbable medical material comes into a hydrogel form when it comes into contact with a small amount of moisture present on the surface of a living tissue, Has been found to produce excellent adhesion. That is, a material was designed in which a porous layer that becomes a hydrogel form by a small amount of water exists on the surface of the bioabsorbable medical material that comes into contact with the living tissue. On the other hand, a film layer having a hydrophilic surface was arranged on the opposite surface, and the material was designed so as to have an effect of preventing adhesion with surrounding tissues. In this way, by using a bioabsorbable medical material having a two-layer structure consisting of a porous layer and a film layer, it exerts the effect of adhering to the wound part to stop, cover, and close, and promote the healing of the wound part Furthermore, the present inventors have found that an excellent effect that is not possible with conventional medical materials can be obtained, that is, adhesion between a wound part and surrounding tissues can be prevented. In addition to having a two-layer structure consisting of a porous layer and a film layer, a thin sheet (two-layer sheet) can give the material flexibility and increase adhesion to the tissue. So, it was found that the strength of the material is improved, so that it becomes a material excellent in handling that is hard to break. In addition, by using a three-layer sheet structure in which reinforcing materials are combined, we have succeeded in making the material more resistant to breakage and excellent in handleability.
本発明の生体吸収性医療材料は生体吸収性高分子からなり、創傷部が治癒した後には生体内で分解吸収され、異物が生体内に残存するようなことはない。また、吸水面は生体組織に密着しやすいことから縫合糸や接着剤を用いなくとも材料を創傷部に密着、固定することができるのみならず、創傷部の止血、閉鎖の効果が得られるものであるが、接着剤などとの併用によってさらに効果を高めることも可能である。また、創傷部に密着する面と反対側の面は親水性であることから、周囲組織との癒着を防止する効果が得られる。すなわち、本発明に係る材料を生体組織の創傷部に押しつけるだけで密着、固定することができ、さらに創傷部への癒着を防止できるという、これまでにない画期的な効果が得られるものである。
また、補強材料と複合化させることによって従来のフィルム状の材料と比較して材料の強度が向上し、一旦組織に密着させた材料を再度移動させることが可能になるばかりでなく、内視鏡手術のように狭い視野で操作を行う場合にも壊れにくいという、これまでにない医療現場で取り扱い性に優れた材料が得られるものである。
The bioabsorbable medical material of the present invention is composed of a bioabsorbable polymer and is decomposed and absorbed in the living body after the wound has healed, so that no foreign matter remains in the living body. In addition, the water-absorbing surface is easy to adhere to living tissue, so that not only can sutures and adhesives be used, but the material can be adhered and fixed to the wound part, as well as the effect of hemostasis and closure of the wound part. However, the effect can be further enhanced by the combined use with an adhesive or the like. Moreover, since the surface on the opposite side to the surface which adheres to a wound part is hydrophilic, the effect which prevents adhesion with a surrounding tissue is acquired. That is, the material according to the present invention can be adhered and fixed simply by pressing against the wound part of the living tissue, and further, an unprecedented effect can be obtained that adhesion to the wound part can be prevented. is there.
In addition, by combining with a reinforcing material, the strength of the material is improved as compared with a conventional film-like material, and it is possible not only to move the material once in close contact with the tissue, but also an endoscope. This makes it possible to obtain a material that is easy to handle at an unprecedented medical site that is difficult to break even when an operation is performed with a narrow visual field, such as surgery.
本発明に係る生体吸収性医療材料を構成する高分子は、生体内で分解吸収されるものであれば特に限定されるものではないが、親水性高分子、特に天然高分子であることが望ましい。このような天然高分子としては、コラーゲン、ゼラチン、ヒアルロン酸、アルギン酸、キチン、キトサンなどを例示することができる。このなかでも、水に溶解させることができ、加工性に優れるゼラチンを用いることが好ましい。 The polymer constituting the bioabsorbable medical material according to the present invention is not particularly limited as long as it is decomposed and absorbed in vivo, but is preferably a hydrophilic polymer, particularly a natural polymer. . Examples of such natural polymers include collagen, gelatin, hyaluronic acid, alginic acid, chitin, and chitosan. Among these, it is preferable to use gelatin that can be dissolved in water and has excellent processability.
これらの天然高分子は生体内ですぐに溶解してしまうことから、何らかの架橋処理がされている必要がある。架橋は加熱処理や紫外線照射、放射線照射などの物理的方法と、グルタルアルデヒドやカルボジイミドなどの架橋剤を用いる化学的方法がある。このうち、材料に架橋剤が残らない加熱処理や紫外線照射などの物理的方法による架橋を行うことが好ましい。 Since these natural polymers are readily dissolved in vivo, some kind of crosslinking treatment needs to be performed. Crosslinking includes physical methods such as heat treatment, ultraviolet irradiation and radiation irradiation, and chemical methods using a crosslinking agent such as glutaraldehyde and carbodiimide. Among these, it is preferable to perform crosslinking by a physical method such as heat treatment or ultraviolet irradiation that does not leave a crosslinking agent in the material.
生体吸収性医療材料が生体内で長期間残存すると、周囲の組織を傷つけ、かえって癒着を引き起こすことになってしまう。一方で、あまりに短期間で分解、吸収されてしまうと、止血や創傷治癒、癒着防止の効果が十分に得られない。本発明の生体吸収性医療材料は、生体内に埋入後12時間は存在していることが必要であり、一方で埋入後90日以内にすみやかに分解、吸収されることが望ましい。 If the bioabsorbable medical material remains in the living body for a long period of time, it will damage surrounding tissues and cause adhesions. On the other hand, if it is decomposed and absorbed in a too short period of time, the effect of hemostasis, wound healing, and adhesion prevention cannot be obtained sufficiently. The bioabsorbable medical material of the present invention needs to exist for 12 hours after implantation in the living body, while it is desirable that the bioabsorbable medical material be quickly decomposed and absorbed within 90 days after implantation.
生体吸収性医療材料を生体組織の創傷部に密着させるためには、生体組織に接着する側の材料表面が、生体組織の少量の水分を吸水し、ヒドロゲル状になる層が存在する必要がある。このような層としては、親水性材料からなる多孔質層があげられる。すなわち、材料表面に吸水を容易にする微少な孔などが多数存在しているような構造であればよい。このような構造としては、編物、織物、不織布のような繊維構造であってもよいし、スポンジのような多孔質構造であってもよい。この中でも、水溶性高分子を用いる場合に作製が容易なスポンジ状の多孔質体からなることが好ましい。このようなスポンジ状の多孔質体からなる多孔質層の存在により、フィブリン糊や縫合糸などを用いなくても、必要な期間、生体組織に生体吸収性医療材料を密着、固定させることができるものである。 In order for the bioabsorbable medical material to adhere to the wound of the living tissue, the surface of the material that adheres to the living tissue needs to have a layer that absorbs a small amount of moisture from the living tissue and becomes a hydrogel. . Examples of such a layer include a porous layer made of a hydrophilic material. That is, any structure may be used as long as the surface of the material has a large number of minute holes that facilitate water absorption. Such a structure may be a fiber structure such as a knitted fabric, a woven fabric or a non-woven fabric, or may be a porous structure such as a sponge. Among these, when using a water-soluble polymer, it is preferable to consist of a sponge-like porous body with easy preparation. Due to the presence of such a porous layer made of a sponge-like porous body, a bioabsorbable medical material can be adhered and fixed to a living tissue for a necessary period without using fibrin glue or sutures. Is.
このようなスポンジ状の多孔質体の製造方法としては、生体吸収性高分子を水などの溶媒に溶解した後に、この溶液を凍結乾燥する方法がある。あるいは、生体吸収性高分子水溶液を発泡しておいてから、その多孔構造を維持しながら凍結乾燥、風乾、あるいは生体吸収性高分子水溶液に非溶媒を加えて相分離させるなどの方法を例示することができる。 As a method for producing such a sponge-like porous body, there is a method in which a bioabsorbable polymer is dissolved in a solvent such as water and then this solution is freeze-dried. Or, a method of foaming a bioabsorbable polymer aqueous solution and then lyophilizing, air drying, or adding a non-solvent to the bioabsorbable polymer aqueous solution while maintaining its porous structure is exemplified. be able to.
スポンジ状の多孔質体の孔径は、1μm〜1,000μmであり、好ましくは5μm〜800μm
の範囲である。孔径が1μmより小さいと生体組織の水が材料に吸い込まないために密着性が悪くなり、材料が創傷部に密着できなくなるためである。一方、1,000μmを超えると孔径が大きすぎるために多孔質体の強度が下がりすぎて破れやすくなってしまうためである。
The pore size of the sponge-like porous body is 1 μm to 1,000 μm, preferably 5 μm to 800 μm.
Range. If the pore diameter is smaller than 1 μm, the water of the living tissue is not sucked into the material, so that the adhesion is deteriorated and the material cannot be adhered to the wound part. On the other hand, if the thickness exceeds 1,000 μm, the pore size is too large, and the strength of the porous body is too low and it is easily broken.
スポンジ状の多孔質体の厚みは20μm〜15,000μmであり、好ましくは50μm〜10,000μmの範囲である。20μm未満であると材料が壊れやすく、一方で15000μm以上であると材料が硬くなり創傷部に密着しなくなってしまうためである。 The thickness of the sponge-like porous body is 20 μm to 15,000 μm, preferably 50 μm to 10,000 μm. If the thickness is less than 20 μm, the material is fragile. On the other hand, if the thickness is 15000 μm or more, the material becomes hard and does not adhere to the wound part.
生体吸収性医療材料が創傷部と周囲組織との癒着を防止するためには、材料が生体組織と接触して密着する面とは反対面の材料表面が親水性のフィルム状であって、かつ、材料表面に細胞や組織が接着しないことが必要である。このような材料としては、親水性で表面が平滑なフィルム状の材料であれば特に限定されるものではない。このフィルム状の材料は、厚ければ柔軟性と操作性に欠けるため、できるだけ薄くすることが必要である。フィルム状の材料の厚さは1μm〜200μmであり、好ましくは2μm〜100μmの範囲である。厚さが1μm未満であると材料が壊れやすいために扱いにくく、一方で200μm以上であると材料が硬く創傷部に密着しなくなってしまうためである。 In order for the bioabsorbable medical material to prevent adhesion between the wound and the surrounding tissue, the surface of the material opposite to the surface where the material contacts and adheres to the living tissue is a hydrophilic film, and It is necessary that cells and tissues do not adhere to the material surface. Such a material is not particularly limited as long as it is a film-like material that is hydrophilic and has a smooth surface. Since this film-like material lacks flexibility and operability when it is thick, it needs to be as thin as possible. The thickness of the film-like material is 1 μm to 200 μm, and preferably 2 μm to 100 μm. If the thickness is less than 1 μm, the material is fragile and difficult to handle. On the other hand, if the thickness is 200 μm or more, the material is too hard to adhere to the wound.
フィルム状の材料の作製方法は特に限定されないが、生体吸収性高分子を溶媒に溶解したのちに、この溶液を型枠に流し込んで溶媒を除去するキャスト法や、溶液を平板上に流延して溶媒を除去する流延法などが例示できる。 The method for producing the film-like material is not particularly limited, but after dissolving the bioabsorbable polymer in a solvent, the solution is poured into a mold to remove the solvent, or the solution is cast on a flat plate. Examples thereof include a casting method in which the solvent is removed.
本発明に係る生体吸収性医療材料は、前述のごとく創傷部と密着する層を構成する多孔質層と、創傷部と周囲組織との癒着を防止するためのフィルム層を構成する材料からなる二層構造であることを特徴とする二層シートである。二層構造とするためには、各層を別個に作製しておいてから複合化させてもよいし、一つの層を作製してからさらにもう一つの層を作製させてもよい。さらには、二つの層を同時に作製させる方法であってもよい。 The bioabsorbable medical material according to the present invention comprises a porous layer that constitutes a layer that adheres to a wound part as described above, and a material that constitutes a film layer for preventing adhesion between the wound part and surrounding tissue. It is a two-layer sheet characterized by having a layer structure. In order to obtain a two-layer structure, each layer may be produced separately and then combined, or one layer may be produced and then another layer may be produced. Furthermore, the method of producing two layers simultaneously may be used.
本願発明に係る生体吸収性医療材料は、二層シートとすることによって操作性がきわめて良好になるものである。材料が水分で膨潤すると柔軟さが生じ、シート状を保った状態で肺のように常に形状の変化する組織に対しても密着し続けることができる。 The bioabsorbable medical material according to the present invention is extremely easy to operate by using a two-layer sheet. When the material swells with moisture, softness is generated, and the material can be kept in close contact with a tissue that constantly changes its shape, such as the lung, while maintaining a sheet shape.
本願発明に係る生体吸収性医療材料は、内視鏡手術で用いることが想定される。内視鏡手術では手術器械を用いて狭い視野で手術を行うこととなり、創傷部に材料を密着させる場合に何度も位置を直すことありうる。このような場合、水分を吸収した材料は柔らかくて壊れやすく、さらなる補強が求められる。 The bioabsorbable medical material according to the present invention is assumed to be used in endoscopic surgery. In endoscopic surgery, surgery is performed with a narrow visual field using a surgical instrument, and when the material is brought into close contact with the wound part, the position may be corrected many times. In such a case, the moisture-absorbing material is soft and fragile, and further reinforcement is required.
補強材料としては、生体吸収性繊維からなる薄い織物、編物、不織布などがあげられる。生体吸収性繊維の材料としては、吸収性高分子であれば特に限定されるものではないが、吸水時に容易に膨潤しない合成の吸収性高分子であることが好ましい。このうち、吸収速度が速いポリグリコリド、グリコリド−ラクチド共重合体、あるいはグリコリド−ε―カプロラクトン共重合体であることがより好ましい。 Examples of the reinforcing material include thin woven fabrics, knitted fabrics, and nonwoven fabrics made of bioabsorbable fibers. The material of the bioabsorbable fiber is not particularly limited as long as it is an absorptive polymer, but is preferably a synthetic absorptive polymer that does not easily swell upon water absorption. Among these, polyglycolide, glycolide-lactide copolymer, or glycolide-ε-caprolactone copolymer having a high absorption rate is more preferable.
本願発明に係る生体吸収性医療材料は、組織への密着性を高めるためには柔軟であることが必要である。そのためには、補強材はできる限り薄く柔軟性があることが必要である。補強材の厚さは5μm〜500μmであり、好ましくは10μm〜400μmの範囲である。5μm未満であると補強材自体の取り扱いが難しく成型が困難になってしまい、一方で500μm以上であると材料が硬く創傷部に密着しなくなってしまうためである。本願発明に係る医療材料は、多孔質層、フィルム層、さらに補強材料の三層構造からなる三層シートであってもよい。 The bioabsorbable medical material according to the present invention needs to be flexible in order to improve the adhesion to the tissue. For this purpose, the reinforcing material needs to be as thin and flexible as possible. The thickness of the reinforcing material is 5 μm to 500 μm, preferably 10 μm to 400 μm. When the thickness is less than 5 μm, it is difficult to handle the reinforcing material itself, and molding becomes difficult. On the other hand, when the thickness is 500 μm or more, the material is hard and does not adhere to the wound part. The medical material according to the present invention may be a three-layer sheet having a three-layer structure of a porous layer, a film layer, and a reinforcing material.
このように、本願発明の生体吸収性医療材料は、創傷部に材料を押し付けることによって密着させることができ、さらには創傷部の止血、閉鎖、組織再生、癒着防止などの種々の組織修復に必要な効果を発揮する。 As described above, the bioabsorbable medical material of the present invention can be brought into close contact with the wound by pressing the material, and further necessary for various tissue repairs such as hemostasis, closure, tissue regeneration, and adhesion prevention of the wound. Exerts a positive effect.
以下、実施例を挙げて本発明を説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated, this invention is not limited to these Examples.
(実施例1)凍結乾燥法による二層シートの作製その1
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流延、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。トレー上に作製した前記ゼラチンフィルムの上から1.0%ゼラチン水溶液を5mL流し込み、25℃にて10分間静置した。その後、トレーを‐80℃の冷凍庫に30分間入れてゼラチン水溶液を凍結させた後、凍結乾燥機中で24時間処理することによりゼラチン多孔質層−フィルム層複合体(二層シート)を作製した。このときのシート全体の厚みは2mmであった。その後、二層シートを真空乾燥機に入れ、真空下、140℃で3時間、熱処理を行うことにより加熱架橋した。得られた二層材料をステンレス板で挟み、上から荷重を5分間かけることによってプレスした。得られた材料のフィルム層は平滑であり、スポンジ層は凸凹のある不透明体であった。材料の厚みは、1.3±0.1mmであった。スポンジ体の孔径は92μmであった。
(Example 1) Production of two-layer sheet by freeze-drying method 1
Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was cast on a plastic tray (8.5 × 5.5 cm) at 25 ° C. for 24 hours. Air-dried to produce a 10 μm thick gelatin film. From the gelatin film prepared on the tray, 5 mL of 1.0% gelatin aqueous solution was poured and allowed to stand at 25 ° C. for 10 minutes. Thereafter, the tray was placed in a freezer at −80 ° C. for 30 minutes to freeze the aqueous gelatin solution, and then processed in a freeze dryer for 24 hours to produce a gelatin porous layer-film layer composite (bilayer sheet). . At this time, the thickness of the entire sheet was 2 mm. Thereafter, the two-layer sheet was placed in a vacuum dryer and heat-crosslinked by heat treatment at 140 ° C. for 3 hours under vacuum. The obtained two-layer material was sandwiched between stainless plates and pressed by applying a load from above for 5 minutes. The film layer of the obtained material was smooth, and the sponge layer was an uneven opaque body. The material thickness was 1.3 ± 0.1 mm. The pore diameter of the sponge body was 92 μm.
(実施例2)凍結乾燥法による二層シートの作製その2
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流延、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。トレー上に作製した前記ゼラチンフィルムの上から1.0%ゼラチン水溶液を10mL流し込み、25℃にて10分間静置した。その後、トレーを‐80℃の冷凍庫に30分間入れてゼラチン水溶液を凍結させた後、凍結乾燥機中で24時間処理することによりゼラチン多孔質層−フィルム層複合体(二層シート)を作製した。このときのシート全体の厚みは4mmであった。その後、二層シートを真空乾燥機に入れ、真空下、140℃で3時間、熱処理を行うことにより加熱架橋した。得られた二層材料をステンレス板で挟み、上から荷重を5分間かけることによってプレスした。得られた材料のフィルム層は平滑であり、スポンジ層は凸凹のある不透明体であった。材料の厚みは、2.5±0.1mmであった。スポンジ体の孔径は98μmであった。
(Example 2) Preparation of bilayer sheet by freeze-drying method 2
Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was cast on a plastic tray (8.5 × 5.5 cm) at 25 ° C. for 24 hours. Air-dried to produce a 10 μm thick gelatin film. From the gelatin film prepared on the tray, 10 mL of 1.0% gelatin aqueous solution was poured and allowed to stand at 25 ° C. for 10 minutes. Thereafter, the tray was placed in a freezer at −80 ° C. for 30 minutes to freeze the aqueous gelatin solution, and then processed in a freeze dryer for 24 hours to produce a gelatin porous layer-film layer composite (bilayer sheet). . At this time, the thickness of the entire sheet was 4 mm. Thereafter, the two-layer sheet was placed in a vacuum dryer and heat-crosslinked by heat treatment at 140 ° C. for 3 hours under vacuum. The obtained two-layer material was sandwiched between stainless plates and pressed by applying a load from above for 5 minutes. The film layer of the obtained material was smooth, and the sponge layer was an uneven opaque body. The thickness of the material was 2.5 ± 0.1 mm. The pore diameter of the sponge body was 98 μm.
(実施例3)凍結乾燥法による二層シートの作製その3
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流延、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。トレー上に作製した前記ゼラチンフィルムの上から0.3%コラーゲン水溶液コラーゲンIP(新田ゼラチン社製)を5mL流し込み、25℃にて10分間静置した。その後、トレーを‐80℃の冷凍庫に30分間入れてゼラチン水溶液を凍結させた後、凍結乾燥機中で24時間処理することによりコラーゲン多孔質層−ゼラチンフィルム層複合体(二層シート)を作製した。このときのシート全体の厚みは1mmであった。その後、二層シートを真空乾燥機に入れ、真空下、140℃で3時間、熱処理を行うことにより加熱架橋した。得られた二層材料をステンレス板で挟み、上から荷重を5分間かけることによってプレスした。得られた材料のフィルム層は平滑であり、スポンジ層は凸凹のある不透明体であった。材料の厚みは、1.3±0.1mmであった。
(Example 3) Production of two-layer sheet by freeze-drying method 3
Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was cast on a plastic tray (8.5 × 5.5 cm) at 25 ° C. for 24 hours. Air-dried to produce a 10 μm thick gelatin film. From the gelatin film prepared on the tray, 5 mL of a 0.3% collagen aqueous solution collagen IP (manufactured by Nitta Gelatin Co., Ltd.) was poured and allowed to stand at 25 ° C. for 10 minutes. After that, the tray is placed in a freezer at -80 ° C for 30 minutes to freeze the gelatin aqueous solution, and then processed in a freeze dryer for 24 hours to produce a collagen porous layer-gelatin film layer composite (bilayer sheet). did. The thickness of the entire sheet at this time was 1 mm. Thereafter, the two-layer sheet was placed in a vacuum dryer and heat-crosslinked by heat treatment at 140 ° C. for 3 hours under vacuum. The obtained two-layer material was sandwiched between stainless plates and pressed by applying a load from above for 5 minutes. The film layer of the obtained material was smooth, and the sponge layer was an uneven opaque body. The material thickness was 1.3 ± 0.1 mm.
(実施例4)発泡法による二層シートの作製その1
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流延、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。続いて、2%ゼラチン水溶液を十分攪拌して起泡させ、起泡させたゼラチン水溶液6gをトレー上に作製した前記ゼラチンフィルムの上から流し込み、ゲル化させた後に25℃で風乾した。このとき得られたシート全体の厚みは1mmであった。
これらの二層シートを真空乾燥機に入れ、真空下、140℃にて3時間、熱処理を行って加熱架橋した。このとき得られたシートのトレー側は平滑なフィルム状であり、空気面は凸凹のあるスポンジ体であった。スポンジ体の孔径は223μmであった。
(Example 4) Production of two-layer sheet by foaming method 1
Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was cast on a plastic tray (8.5 × 5.5 cm) at 25 ° C. for 24 hours. Air-dried to produce a 10 μm thick gelatin film. Subsequently, a 2% gelatin aqueous solution was sufficiently agitated to foam, and 6 g of the foamed gelatin aqueous solution was poured from above the gelatin film prepared on the tray to gelate, and then air dried at 25 ° C. The thickness of the entire sheet obtained at this time was 1 mm.
These two-layer sheets were put in a vacuum dryer, and heat-crosslinked under heat at 140 ° C. for 3 hours under vacuum. The tray side of the sheet obtained at this time was a smooth film, and the air surface was a sponge body with irregularities. The pore diameter of the sponge body was 223 μm.
(実施例5)発泡法による二層シートの作製その2
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm2)に流延、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。続いて、4.5%ゼラチン水溶液を十分攪拌して起泡させ、起泡させたゼラチン水溶液3gをトレー上に作製した前記ゼラチンフィルムの上から流し込み、−20℃でゲル化させた後に25℃で風乾した。このとき得られたシート全体の厚みは48μmであった。
これらの二層シートを真空乾燥機に入れ、真空下、140℃にて3時間、熱処理を行って加熱架橋した。このとき得られたシートのトレー側は平滑なフィルム状であり、空気面は凸凹のあるスポンジ体であった。スポンジ体の孔径は147μmであった。
(Example 5) Production of two-layer sheet by foaming method 2
Gelatin powder (Nippi) is dissolved in water for injection to prepare a 1.4% gelatin aqueous solution. 4 mL of this 1.4% gelatin aqueous solution is cast on a plastic tray (8.5 x 5.5 cm 2 ), air-dried at 25 ° C for 24 hours. Thus, a 10 μm thick gelatin film was produced. Subsequently, a 4.5% gelatin aqueous solution was sufficiently stirred to foam, and 3 g of the foamed gelatin aqueous solution was poured onto the gelatin film prepared on the tray, gelled at −20 ° C., and then air-dried at 25 ° C. did. The thickness of the entire sheet obtained at this time was 48 μm.
These two-layer sheets were put in a vacuum dryer, and heat-crosslinked under heat at 140 ° C. for 3 hours under vacuum. The tray side of the sheet obtained at this time was a smooth film, and the air surface was a sponge body with irregularities. The pore diameter of the sponge body was 147 μm.
(実施例6)発泡法による二層シートの作製その3
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流延した。続いて、2%ゼラチン水溶液を十分攪拌して起泡させ、起泡させたゼラチン水溶液6gトレー上に作製した前記ゼラチンフィルムの上から流し込み、ゲル化させた後に25℃で風乾した。このとき得られたシート全体の厚みは1mmであった。
これらの二層シートを真空乾燥機に入れ、真空下、140℃にて1、3、5、8時間、熱処理を行って加熱架橋した。このとき得られたシートのトレー側は平滑なフィルム状であり、空気面は凸凹のあるスポンジ体であった。スポンジ体の孔径は223μmであった。
(Example 6) Production of two-layer sheet by foaming method 3
Gelatin powder (Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was cast on a plastic tray (8.5 × 5.5 cm). Subsequently, a 2% gelatin aqueous solution was sufficiently agitated to foam, and the foamed gelatin aqueous solution was poured onto the gelatin film prepared on the 6 g tray, gelled, and then air-dried at 25 ° C. The thickness of the entire sheet obtained at this time was 1 mm.
These two-layer sheets were put into a vacuum dryer and heat-crosslinked under heat at 140 ° C. for 1, 3, 5, and 8 hours under vacuum. The tray side of the sheet obtained at this time was a smooth film, and the air surface was a sponge body with irregularities. The pore diameter of the sponge body was 223 μm.
(実施例7)発泡法による二層シートの作製その3
ゼラチン粉末(ニッピ社製)を注射用水に溶解して2%のゼラチン水溶液を調製し、十分攪拌して起泡させ、起泡させたゼラチン水溶液6gをガラストレー(8.5×5.5cm)に流し込み、ゲル化させた後に25℃で風乾した。このとき得られたシート全体の厚みは5mmであった。このシートを真空乾燥機に入れ、真空下、140℃にて3時間、熱処理を行って加熱架橋した。このとき得られたシートのガラス板側は平滑なフィルム状であり、空気面は凸凹のあるスポンジ体であった。スポンジ体の孔径は223μmであった。
(Example 7) Production of two-layer sheet by foaming method 3
Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 2% gelatin aqueous solution, sufficiently stirred to foam, and 6 g of the foamed gelatin aqueous solution was poured into a glass tray (8.5 × 5.5 cm). After gelation, it was air-dried at 25 ° C. The thickness of the entire sheet obtained at this time was 5 mm. This sheet was put into a vacuum dryer and heat-crosslinked under heat at 140 ° C. for 3 hours under vacuum. The glass plate side of the sheet obtained at this time was a smooth film, and the air surface was an uneven sponge body. The pore diameter of the sponge body was 223 μm.
(実施例4)相分離法による二層シートの作製
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流し込み、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。続いて、2%ゼラチン水溶液をトレー上に作製した前記ゼラチンフィルムの上から流し込み、その上に冷却したエタノール(10ml)をさらに流し込み、ゼラチンを沈殿させた。エタノールを用いて洗浄後、25℃で風乾した。得られた二層シートの表面には白濁したゼラチン沈殿物が固着しており、凸凹であった。
(Example 4) Preparation of bilayer sheet by phase separation method Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was added to a plastic tray (8.5). × 5.5 cm) and air-dried at 25 ° C. for 24 hours to produce a 10 μm thick gelatin film. Subsequently, a 2% gelatin aqueous solution was poured onto the gelatin film prepared on the tray, and cooled ethanol (10 ml) was further poured thereon to precipitate the gelatin. After washing with ethanol, it was air-dried at 25 ° C. A cloudy gelatin precipitate was fixed on the surface of the obtained two-layer sheet, and was uneven.
(実施例9)補強材入り三層シートの作製
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、この1.4%ゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流し込み、25℃、24時間、風乾して厚さ10μmのゼラチンフィルムを作製した
トレー上に作製した前記ゼラチンフィルムの上に、補強材となるポリグリコリド繊維からなる経編布(12g/cm2)を置いた。続いて、2%ゼラチン水溶液を十分攪拌して起泡させ、起泡させたゼラチン水溶液6gをトレー上に作製した前記ゼラチンフィルムとポリグリコリド繊維からなる経編布の上から流し込み、ゲル化させた後に25℃で風乾した。このとき得られたシート全体の厚みは1mmであった。これらの二層シートを真空乾燥機に入れ、真空下、140℃にて3時間、熱処理を行って加熱架橋した。このとき得られたシートのトレー側は平滑なフィルム状であり、空気面は凸凹のあるスポンジ体であった。スポンジ体の孔径は223μmであった。
補強材としては、前記経編布以外に、ポリグリコリド不織布(ニードルパンチ)、ポリグリコリド不織布(メルトブロー)を用いた。
(Example 9) Preparation of three-layer sheet with reinforcing material Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this 1.4% gelatin aqueous solution was added to a plastic tray (8.5 × 5cm), air-dried at 25 ° C for 24 hours, and a warp knitted fabric consisting of polyglycolide fibers (12g) as a reinforcing material on the gelatin film prepared on a tray made of a 10μm thick gelatin film / cm 2 ). Subsequently, the 2% gelatin aqueous solution was sufficiently stirred to foam, and 6 g of the foamed gelatin aqueous solution was poured onto the warp knitted fabric made of the gelatin film and polyglycolide fiber prepared on the tray, and gelled. Later it was air dried at 25 ° C. The thickness of the entire sheet obtained at this time was 1 mm. These two-layer sheets were put in a vacuum dryer, and heat-crosslinked under heat at 140 ° C. for 3 hours under vacuum. The tray side of the sheet obtained at this time was a smooth film, and the air surface was a sponge body with irregularities. The pore diameter of the sponge body was 223 μm.
As the reinforcing material, in addition to the warp knitted fabric, a polyglycolide nonwoven fabric (needle punch) and a polyglycolide nonwoven fabric (melt blow) were used.
(比較例1)一層フィルムの作製
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1.4%のゼラチン水溶液を調製し、このゼラチン水溶液4mLをプラスチックトレー(8.5×5.5cm)に流延、25℃にて24時間、風乾して厚さ10μmのゼラチンフィルムを作製した。得られたゼラチンフィルムを真空乾燥機中、140℃で3時間熱処理を行うことにより熱架橋した。得られたフィルムは両面とも平滑な透明体であり、60℃の温水に不溶であった。
Comparative Example 1 Preparation of Single Layer Film Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1.4% gelatin aqueous solution, and 4 mL of this gelatin aqueous solution was cast on a plastic tray (8.5 × 5.5 cm), 25 A gelatin film having a thickness of 10 μm was prepared by air-drying at 24 ° C. for 24 hours. The obtained gelatin film was heat-crosslinked by heat treatment at 140 ° C. for 3 hours in a vacuum dryer. The obtained film was a smooth transparent body on both sides, and was insoluble in hot water at 60 ° C.
(比較例2)一層スポンジ状シートの作製
ゼラチン粉末(ニッピ社製)を注射用水に溶解して1%のゼラチン水溶液を調製し、この1%ゼラチン水溶液1mLをプラスチックトレー(8.5×5.5cm)に流し込み、−80℃の冷凍庫で凍結した。その後、凍結乾燥器に24時間入れてスポンジを作製した。得られた多孔質層の厚みは〜1mmであった。得られたスポンジシートは実施例1〜7において得られた二層シート、あるいは実施例8において得られた三層シートとは異なり、手で引張るだけで容易に引き裂かれ、脆弱であるために本発明の目的を達しなかった。
(Comparative Example 2) Preparation of a single-layer sponge sheet Gelatin powder (manufactured by Nippi) was dissolved in water for injection to prepare a 1% gelatin aqueous solution, and 1 mL of this 1% gelatin aqueous solution was placed in a plastic tray (8.5 × 5.5 cm). Poured and frozen in a −80 ° C. freezer. Then, it was put into a freeze dryer for 24 hours to produce a sponge. The thickness of the obtained porous layer was ˜1 mm. Unlike the two-layer sheet obtained in Examples 1 to 7 or the three-layer sheet obtained in Example 8, the obtained sponge sheet is easily torn and brittle by simply pulling it by hand. The object of the invention was not achieved.
(引張強度の評価)
実施例4で作製した二層シートおよび実施例8で作製した三層シートを湿潤状態で測定したときの引張り強度を図2に示す。湿潤状態下での強度は、シート全体を湿潤させてしまうと試験機のチャックにはさむことができなかったため、乾燥シートをチャックにはさんでからシート中央の長さ1cm部分のみを水で潤潤させて測定した。
図2にみられるように、PGA布の種類によって湿潤強度に若干の差は認められたが、いずれも、補強なしシートの湿潤強度よりは明らかに高値であった。
(Evaluation of tensile strength)
FIG. 2 shows the tensile strength when the two-layer sheet prepared in Example 4 and the three-layer sheet prepared in Example 8 were measured in a wet state. The strength under wet conditions could not be held by the chuck of the testing machine if the entire sheet was wetted, so only the 1cm length in the center of the sheet was moistened with water. And measured.
As can be seen in FIG. 2, there was a slight difference in wet strength depending on the type of PGA fabric, but all were clearly higher than the wet strength of the unreinforced sheet.
(吸水性の評価)
実施例4で作製した二層シートおよび実施例8で作製した三層シートの吸水性を次の方法によって評価した。対照として、比較例1で作製したゼラチンフィルムを用いた。まず、リン酸緩衝生理食塩水を30mg/cm2となるように水平な台上に滴下し、その上に1cm2の乾燥した二層シートあるいは三層シートを静置した。シートを水平な台に置いてからのシートの吸水量の時間変化を図3に示した。比較のために、比較例1で作製したゼラチン一層シートについても測定した。図2に示されるように二層シートおよび三層シートはすみやかに水分を吸収しているのに対して、比較例のゼラチン一層シートは水分を吸水するのに時間がかかった。
(Evaluation of water absorption)
The water absorption of the two-layer sheet produced in Example 4 and the three-layer sheet produced in Example 8 was evaluated by the following method. As a control, the gelatin film prepared in Comparative Example 1 was used. First, phosphate buffered saline was dropped onto a horizontal table so as to be 30 mg / cm 2, and 1 cm 2 of a dried two-layer sheet or three-layer sheet was allowed to stand thereon. The time change of the water absorption amount of the sheet after placing the sheet on a horizontal table is shown in FIG. For comparison, the gelatin single layer sheet prepared in Comparative Example 1 was also measured. As shown in FIG. 2, the two-layer sheet and the three-layer sheet quickly absorbed moisture, whereas the comparative gelatin layer sheet took time to absorb moisture.
(分解性評価)
実施例4で作製した二層シート(1×1cm2)について、in vivoでの分解性を下記の方法で評価した。麻酔下でラットの皮下に、重量を測定した滅菌シートを埋入し、1、3、5、7、10日後にシートを取り出した。洗浄後、乾燥させ、分解吸収後の残量を測定した。結果を図4に示す。
(Degradability evaluation)
The in vivo degradability of the bilayer sheet (1 × 1 cm 2 ) produced in Example 4 was evaluated by the following method. Under anesthesia, the sterilized sheet weighed was placed under the skin of the rat, and the sheet was taken out after 1, 3, 5, 7, and 10 days. After washing and drying, the remaining amount after decomposition and absorption was measured. The results are shown in FIG.
(生体組織への密着性評価)
実施例1で作製した二層シート(厚み1.3mm)、実施例2で作製した二層シート(厚み2.5mm)、比較例1で作製したゼラチン一層フィルム、および市販のヒアルロン酸とカルボキシメチルセルロースからなるフィルム(商品名セプラフィルム)の生体組織への密着性を、下記の方法により評価した。実施例1で作製した二層シートあるいはセプラフィルム(1cm×1cm)の片面にテープを貼り、その真ん中に糸を通した。犠牲死させたラットの盲腸に二層シートあるいはセプラフィルムを貼り、30秒間指で押さえて密着させた。糸に強力測定器を取り付け、垂直にゆっくりと引張り、剥がれるときの強度を測定した。試験を2回行ったときの引張強度は、実施例1で作製した二層シートは117.5±10.6gf/cm2であったのに対して、セプラフィルムは70.0±42.4gf/cm2で、組織への密着性は二層シートの方が優れていた。
また、ブタの肝臓に対する密着性評価のために、実施例1で作製した二層シート(厚み1.3mm)、実施例2で作製した二層シート(厚み2.5mm)、および比較例1で作製したゼラチンフィルムの生体組織への密着性を、下記の方法により評価した。まず、二層シートあるいはゼラチンフィルム(2×4cm2) の片面にテープを貼り、その真ん中に糸を通した。犠牲死させたブタの肝臓にフィルムあるいはシートを貼り、30秒間指で押さえて密着させた。糸に強力測定器を取り付け、垂直にゆっくりと引張り、剥がれるときの強度を測定した。試験を5回行ったときの引張強度は実施例1の二層シートは14.0±3.7gf/cm2(二層シート、厚み1.3mm)、29.0±11.3gf/cm2(二層シート、厚み2.5mm)であったのに対して、比較例1のゼラチンフィルムは9.9±3.7gf/cm2(フィルム)で、組織への密着性は二層シートの方が優れていた。
(Evaluation of adhesion to living tissue)
The bilayer sheet (thickness 1.3 mm) produced in Example 1, the bilayer sheet (thickness 2.5 mm) produced in Example 2, the gelatin single layer film produced in Comparative Example 1, and a commercially available hyaluronic acid and carboxymethylcellulose. The adhesion of the film (trade name Sepra film) to the living tissue was evaluated by the following method. Tape was applied to one side of the double-layer sheet or Sepra film (1 cm × 1 cm) produced in Example 1, and a thread was passed through the middle. A bilayer sheet or Sepra film was applied to the cecum of the sacrificed rat, and it was brought into close contact with a finger for 30 seconds. A strength measuring device was attached to the yarn, and it was slowly pulled vertically to measure the strength when it was peeled off. The tensile strength when the test was performed twice was 117.5 ± 10.6 gf / cm 2 for the double-layer sheet prepared in Example 1, whereas that for Sepra film was 70.0 ± 42.4 gf / cm 2 . The two-layer sheet was superior in adhesion to the surface.
In addition, for the evaluation of adhesion to the pig liver, the bilayer sheet (thickness 1.3 mm) produced in Example 1, the bilayer sheet (thickness 2.5 mm) produced in Example 2, and the comparative example 1 were produced. The adhesion of the gelatin film to the living tissue was evaluated by the following method. First, a tape was applied to one side of a two-layer sheet or a gelatin film (2 × 4 cm 2), and a thread was passed through the middle. A film or sheet was affixed to the liver of a sacrificed pig and brought into close contact with a finger for 30 seconds. A strength measuring device was attached to the yarn, and it was slowly pulled vertically to measure the strength when it was peeled off. Tensile strength when the test is conducted 5 times is 14.0 ± 3.7 gf / cm2 (double layer sheet, thickness 1.3 mm), 29.0 ± 11.3 gf / cm2 (double layer sheet, thickness 2.5 mm) of the double layer sheet of Example 1. In contrast, the gelatin film of Comparative Example 1 was 9.9 ± 3.7 gf / cm 2 (film), and the double-layer sheet was superior in adhesion to the tissue.
(止血性評価)
実施例1および2で作製した二層シートの止血効果を下記の方法により評価した。麻酔下でラットの腹部を切開して胃を露出させ、前壁に0.5×0.5cm2の上皮剥離創を作製して組織から出血させた。ガーゼを30秒間創部に押し付けても止血できないことを確認してから、創部に1×2cm2の二層シートを置き、30秒間、ピンセットで押し付けた。その結果、いずれの二層シートも創部に密着し、5分後においても止血効果が認められた。
(Evaluation of hemostasis)
The hemostatic effect of the bilayer sheet produced in Examples 1 and 2 was evaluated by the following method. Under anesthesia, the abdomen of the rat was incised to expose the stomach, and a 0.5 × 0.5 cm 2 epithelial exfoliation was created on the anterior wall and allowed to bleed from the tissue. After confirming that gauze was pressed against the wound for 30 seconds and hemostasis could not be achieved, a 1 × 2 cm 2 double-layer sheet was placed on the wound and pressed with tweezers for 30 seconds. As a result, any two-layer sheet adhered to the wound, and a hemostatic effect was observed even after 5 minutes.
(圧迫による止血性評価)
実施例4で作製した二層シートと実施例8で作製した三層シートの圧迫による止血効果を下記の方法により評価した。麻酔下でイヌの腹部を切開して脾臓を露出させ、前壁に1.0×1.0cm2の上皮剥離創を作製し、出血させて出血量の多いモデルを作製した。ガーゼで30秒間、押しても止血できないことを確認してから、創部に2×2cm2の二層シートあるいは三層シートを置き、さらにシートの上にガーゼを置いた。ガーゼの上から5分間強く押し付けた。その結果、出血量の多い場合では、二層シートは形がくずれてガーゼに接着して組織から剥がれてしまったが、三層シートは患部に密着し、止血効果が認められた。
(Evaluation of hemostasis by compression)
The hemostatic effect by compression of the two-layer sheet produced in Example 4 and the three-layer sheet produced in Example 8 was evaluated by the following method. Under anesthesia, the abdomen of the dog was incised to expose the spleen, and a 1.0 × 1.0 cm 2 epithelial exfoliation wound was created on the anterior wall, and bleeding was performed to create a model with a large amount of bleeding. After confirming that hemostasis could not be stopped by pressing with gauze for 30 seconds, a 2 × 2 cm 2 bilayer sheet or a trilayer sheet was placed on the wound, and gauze was further placed on the sheet. The gauze was pressed firmly for 5 minutes. As a result, when the amount of bleeding was large, the two-layer sheet was deformed and adhered to the gauze and peeled off from the tissue. However, the three-layer sheet adhered to the affected area, and a hemostatic effect was observed.
(癒着防止効果の評価)
実施例4で作製した二層シートについて、癒着防止効果を下記の方法により評価した。創傷部位に
麻酔下でラットの腹部を切開し、盲腸前壁と腹膜に癒着を起こすように15mm径の漿膜をゆるく傷つけた。その上に2×2cm2の大きさの二層シートを置き、30秒間押し付けた。ゼラチン製の医療用接着剤を塗布してから、二層シートを置き、同様の操作を行った。対照例として市販のヒアルロン酸とカルボキシメチルセルロースからなるフィルム(商品名セプラフィルム)を用いた。また、創傷部位に何も置かず腹部を縫合した例を作製した(Sham Ope)。2週間後に開腹して癒着の有無を観察し、癒着スコア(0=癒着無し、1=mild、2=moderate、3=severe、4=very severe)を用いて、癒着防止効果を各6匹のラットモデルで評価した。評価結果を図5に示す。いかなる材料も用いずに組織面を傷つけたままに放置しておいた場合には6匹すべてに強い癒着が生じ、セプラフィルムを組織面に密着させた場合は6匹中2匹癒着していたのに対し、二層シートを組織面に密着させた場合には、6匹中1匹しか癒着が認められなかった。また、二層シートを接着剤と併用した場合では3匹すべてに癒着が認められなかった。
(Evaluation of adhesion prevention effect)
About the double-layer sheet produced in Example 4, the adhesion prevention effect was evaluated by the following method. Under anesthesia, the abdomen of the rat was incised at the wound site, and the serosa with a diameter of 15 mm was loosely injured so as to cause adhesion between the anterior cecum wall and peritoneum. A 2 × 2 cm 2 size double layer sheet was placed thereon and pressed for 30 seconds. After the gelatin medical adhesive was applied, a two-layer sheet was placed and the same operation was performed. As a control example, a commercially available film (trade name Sepra film) composed of hyaluronic acid and carboxymethylcellulose was used. In addition, an example was prepared in which the abdomen was sutured without placing anything on the wound site (Sham Ope). Two weeks later, the abdomen was observed and the presence or absence of adhesion was observed. Using adhesion scores (0 = no adhesion, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe) The rat model was evaluated. The evaluation results are shown in FIG. When no tissue was used and the tissue surface was left injured, strong adhesion occurred in all six mice, and when Sepra film was adhered to the tissue surface, two of the six mice adhered. On the other hand, when the two-layer sheet was brought into close contact with the tissue surface, only 1 out of 6 animals showed adhesion. In addition, when the two-layer sheet was used in combination with an adhesive, no adhesion was observed in all three animals.
(空気漏れ防止効果)
実施例1、4および5で作製した二層シートの空気漏れ(Air leak)防止効果を下記の方法で評価した。犠牲死させたイヌの肺に空気を入れ、圧を5cm/H2Oに保ちながら18G針で穿刺して孔を作製した。空気漏れを確認した後、実施例1で得られた1.5×1.5cm2の大きさの二層シートを、孔が真ん中にくるように置き、30秒間、圧迫してから圧をゆっくりと高めていった。いずれの二層シートを用いた場合でも、空気漏れの生じた圧は56cm/H2Oであった。
二層シートの周辺部に、さらにゼラチン製の医療用接着剤を塗布した場合、空気漏れの生じた圧は80 cm/H2Oであった。同様の実験をフィブリン糊(商品名ベリプラスト)を用いて行ったときの結果は38 cm/H2Oであり、二層シート、あるいはシートと接着剤の併用材料のほうが高い値であった。ヒトが咳をした時に必要な耐圧は50 cm/H2Oであるため、これらの材料の空気漏れ防止効果は十分に認められた。
(Air leak prevention effect)
The air leak prevention effect of the bilayer sheet produced in Examples 1, 4 and 5 was evaluated by the following method. Air was introduced into the lung of a sacrificed dog, and a hole was created by puncturing with an 18G needle while maintaining the pressure at 5 cm / H 2 O. After confirming air leakage, place the two-layer sheet of 1.5 × 1.5 cm 2 obtained in Example 1 so that the hole is in the middle, press for 30 seconds, and then slowly increase the pressure. It was. Even when any two-layer sheet was used, the pressure at which air leaked was 56 cm / H 2 O.
When a gelatin medical adhesive was further applied to the periphery of the two-layer sheet, the pressure at which air leaked was 80 cm / H 2 O. When a similar experiment was performed using fibrin glue (trade name Veriplast), the result was 38 cm / H 2 O, which was higher in the double-layer sheet or the combination material of the sheet and the adhesive. Since the pressure resistance required when a human coughs is 50 cm / H 2 O, the air leakage prevention effect of these materials was sufficiently recognized.
(組織再生能)
実施例1で作製した二層シート、市販のヒアルロン酸とカルボキシメチルセルロースからなるフィルム(商品名セプラフィルム)、および材料を何も用いなかった場合についての、創傷部の組織再生効果を下記の方法で評価した。まず、麻酔下でイヌの腹部を切開し、回盲部から口側10cmの漿膜を4×3cm2だけ紙やすりでゆるく削りとり創傷部を作製した。止血後、創傷部に5×4.5cm2の大きさの二層シートあるいは、ヒアルロン酸フィルムを置き、30秒間押し付けた。対比として、材料を何も置かずに腹部を縫合した。3週間後に開腹して癒着の有無を観察してから患部を切り取り、ホルマリン固定した後に組織切片を作製して、腹膜中皮を酵素抗体法によりHBME1抗体にて染色した。二層シートを用いた場合の組織切片像を図6に、ヒアルロン酸とカルボキシメチルセルロースからなるフィルムを用いた場合の組織切片像を図7に示す。その結果、いずれの二層シートでも中皮の再生が確認できたが、ヒアルロン酸フィルム中皮の再生は確認できなかった。
(Organizational regeneration ability)
The tissue regeneration effect of the wound part in the case where no bilayer sheet prepared in Example 1, a commercially available hyaluronic acid and carboxymethylcellulose film (trade name Sepra film), and any material was used was as follows. evaluated. First, an incision was made in the abdomen of the dog under anesthesia, and a 10 cm serosa from the ileocecal region was gently scraped by 4 × 3 cm 2 with a sandpaper to create a wound. After hemostasis, a double-layer sheet of 5 × 4.5 cm 2 or a hyaluronic acid film was placed on the wound and pressed for 30 seconds. In contrast, the abdomen was sutured without any material. After 3 weeks, the abdomen was opened and the presence or absence of adhesion was observed. The affected area was excised, fixed in formalin, and then a tissue section was prepared. The peritoneal mesothelial was stained with HBME1 antibody by the enzyme antibody method. FIG. 6 shows a tissue slice image when a bilayer sheet is used, and FIG. 7 shows a tissue slice image when a film made of hyaluronic acid and carboxymethylcellulose is used. As a result, regeneration of the mesothelum was confirmed in any two-layer sheet, but regeneration of the hyaluronic acid film mesentery was not confirmed.
(水漏れ防止効果の評価)
実施例4で作製した二層シート、実施例7で作製した三層シートについて、水漏れ防止効果を下記の方法で評価した。トリ胸肉に穴を開けて内径1mmのチューブを挿入し、チューブ末端をトリ胸肉表面の開口部に固定した。チューブ内に水が一定量流れるようポンプを配置し、トリ胸肉表面の開口部から水が流れる水漏れ評価モデルを作製した。流量0.5mL/minの水漏れ評価モデルにおいて、2×2cm2の大きさの二層シートあるいは三層シートを開口部に貼付し、ゼラチン製の医療用接着剤をシート周囲に塗付した。対比として、二層シートあるいは三層シートを用いずにゼラチン製の医療用接着剤のみを開口部に塗付した。その結果、二層シートあるいは三層シートを用いた場合は、シートがトリ胸肉から外れることなく吸水して開口部からの水漏れを防止できたが、二層シートあるいは三層シートを用いなかった場合は、ゼラチン製の医療用接着剤がトリ胸肉から外れて開口部からの水漏れを防止できなかった。
(Evaluation of water leakage prevention effect)
About the two-layer sheet produced in Example 4 and the three-layer sheet produced in Example 7, the water leakage prevention effect was evaluated by the following method. A hole was made in the chicken breast and a tube with an inner diameter of 1 mm was inserted, and the end of the tube was fixed to the opening on the surface of the chicken breast. A pump was arranged so that a certain amount of water would flow in the tube, and a water leakage evaluation model was prepared in which water flows from the opening on the surface of the chicken breast. In a water leak evaluation model with a flow rate of 0.5 mL / min, a 2 × 2 cm 2 size two-layer sheet or three-layer sheet was pasted on the opening, and gelatin medical adhesive was applied around the sheet. As a comparison, only the gelatin medical adhesive was applied to the opening without using a two-layer sheet or a three-layer sheet. As a result, when a two-layer sheet or a three-layer sheet was used, the sheet could absorb water without coming off the chicken breast and prevent water leakage from the opening, but the two-layer sheet or three-layer sheet was not used. In this case, the gelatinous medical adhesive was removed from the chicken breast, and water leakage from the opening could not be prevented.
本発明の生体吸収性医療材料は、外科手術において、生体組織の創傷部において、止血、空気漏れ防止、組織再生能、癒着防止効果を発揮するものである。 The bioabsorbable medical material of the present invention exhibits hemostasis, air leakage prevention, tissue regeneration ability, and adhesion prevention effects in surgical wounds in wounds of biological tissues.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010244193A JP2012095731A (en) | 2010-10-29 | 2010-10-29 | Bioabsorbable medical material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010244193A JP2012095731A (en) | 2010-10-29 | 2010-10-29 | Bioabsorbable medical material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2012095731A true JP2012095731A (en) | 2012-05-24 |
Family
ID=46388389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010244193A Pending JP2012095731A (en) | 2010-10-29 | 2010-10-29 | Bioabsorbable medical material |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2012095731A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014192803A1 (en) * | 2013-05-31 | 2014-12-04 | 学校法人同志社 | Tissue regeneration matrix |
| WO2018061323A1 (en) * | 2016-09-30 | 2018-04-05 | 株式会社ジーシー | Manufacturing method for bioabsorbable membrane and bioabsorbable membrane |
| KR20180137763A (en) * | 2017-06-19 | 2018-12-28 | 주식회사 나이벡 | An assembled biomaterial for bone tissue regeneration and method for preparing the same |
| JP2019076169A (en) * | 2017-10-20 | 2019-05-23 | ニプロ株式会社 | SHEET-LIKE HEMOSTATIC AGENT USING POLY-γ-GLUTAMIC ACID AND METHOD FOR MANUFACTURING THE SAME |
| JP2020130541A (en) * | 2019-02-18 | 2020-08-31 | 青葉化成株式会社 | Medical materials and their manufacturing methods |
| CN115845115A (en) * | 2023-03-03 | 2023-03-28 | 西湖大学 | Silk protein-based double-layer material and preparation method and application thereof |
| WO2024024765A1 (en) * | 2022-07-25 | 2024-02-01 | 東レ株式会社 | Multilayer object |
| US12251491B2 (en) | 2019-03-20 | 2025-03-18 | Astellas Pharma Inc. | Thrombin-carrying hemostatic sheet |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5951849A (en) * | 1982-09-18 | 1984-03-26 | 日東電工株式会社 | Wound cover agent |
| JPS63111873A (en) * | 1986-10-31 | 1988-05-17 | 日本ゼオン株式会社 | Wound cover material |
| JPS63115564A (en) * | 1986-10-31 | 1988-05-20 | 日本ゼオン株式会社 | Wound cover material |
| JPH04135483A (en) * | 1990-09-27 | 1992-05-08 | Kanebo Ltd | Two-layered gelatin and method for preparing the same |
| JP2004148014A (en) * | 2002-10-31 | 2004-05-27 | Nipro Corp | Biodegradable substrate, prosthetic material for tissue regeneration, and cultured tissue |
| JP2004209228A (en) * | 2002-12-16 | 2004-07-29 | Gunze Ltd | Medical film |
| JP2007044080A (en) * | 2005-08-05 | 2007-02-22 | Gunze Ltd | Anti-adhesion membrane |
| WO2009019995A1 (en) * | 2007-08-09 | 2009-02-12 | Gunze Limited | Prosthetic material for living organ |
-
2010
- 2010-10-29 JP JP2010244193A patent/JP2012095731A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5951849A (en) * | 1982-09-18 | 1984-03-26 | 日東電工株式会社 | Wound cover agent |
| JPS63111873A (en) * | 1986-10-31 | 1988-05-17 | 日本ゼオン株式会社 | Wound cover material |
| JPS63115564A (en) * | 1986-10-31 | 1988-05-20 | 日本ゼオン株式会社 | Wound cover material |
| JPH04135483A (en) * | 1990-09-27 | 1992-05-08 | Kanebo Ltd | Two-layered gelatin and method for preparing the same |
| JP2004148014A (en) * | 2002-10-31 | 2004-05-27 | Nipro Corp | Biodegradable substrate, prosthetic material for tissue regeneration, and cultured tissue |
| JP2004209228A (en) * | 2002-12-16 | 2004-07-29 | Gunze Ltd | Medical film |
| JP2007044080A (en) * | 2005-08-05 | 2007-02-22 | Gunze Ltd | Anti-adhesion membrane |
| WO2009019995A1 (en) * | 2007-08-09 | 2009-02-12 | Gunze Limited | Prosthetic material for living organ |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014192803A1 (en) * | 2013-05-31 | 2014-12-04 | 学校法人同志社 | Tissue regeneration matrix |
| US11110204B2 (en) | 2016-09-30 | 2021-09-07 | Gc Corporation | Method of producing bioabsorbable membrane |
| WO2018061323A1 (en) * | 2016-09-30 | 2018-04-05 | 株式会社ジーシー | Manufacturing method for bioabsorbable membrane and bioabsorbable membrane |
| KR20190045262A (en) * | 2016-09-30 | 2019-05-02 | 가부시키가이샤 지씨 | A method of manufacturing a bioabsorbable membrane and a bioabsorbable membrane |
| CN109803692A (en) * | 2016-09-30 | 2019-05-24 | 株式会社Gc | The manufacturing method and bioabsorbable membrane of bioabsorbable membrane |
| JPWO2018061323A1 (en) * | 2016-09-30 | 2019-07-11 | 株式会社ジーシー | Method of manufacturing bioabsorbable membrane and bioabsorbable membrane |
| EP3520829A4 (en) * | 2016-09-30 | 2020-05-06 | GC Corporation | METHOD FOR MANUFACTURING BIOABSORBABLE MEMBRANE AND ASSOCIATED BIOABSORBABLE MEMBRANE |
| KR102227396B1 (en) * | 2016-09-30 | 2021-03-11 | 가부시키가이샤 지씨 | Bioabsorbable membrane manufacturing method and bioabsorbable membrane |
| KR20180137763A (en) * | 2017-06-19 | 2018-12-28 | 주식회사 나이벡 | An assembled biomaterial for bone tissue regeneration and method for preparing the same |
| KR102183048B1 (en) | 2017-06-19 | 2020-11-25 | 주식회사 나이벡 | An assembled biomaterial for bone tissue regeneration and method for preparing the same |
| JP2019076169A (en) * | 2017-10-20 | 2019-05-23 | ニプロ株式会社 | SHEET-LIKE HEMOSTATIC AGENT USING POLY-γ-GLUTAMIC ACID AND METHOD FOR MANUFACTURING THE SAME |
| JP2020130541A (en) * | 2019-02-18 | 2020-08-31 | 青葉化成株式会社 | Medical materials and their manufacturing methods |
| JP7303511B2 (en) | 2019-02-18 | 2023-07-05 | 青葉化成株式会社 | Medical material and its manufacturing method |
| US12251491B2 (en) | 2019-03-20 | 2025-03-18 | Astellas Pharma Inc. | Thrombin-carrying hemostatic sheet |
| WO2024024765A1 (en) * | 2022-07-25 | 2024-02-01 | 東レ株式会社 | Multilayer object |
| CN115845115A (en) * | 2023-03-03 | 2023-03-28 | 西湖大学 | Silk protein-based double-layer material and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012095731A (en) | Bioabsorbable medical material | |
| JP4812630B2 (en) | Tissue coating assemblies, systems and methods formed from hydrophilic polymer sponge structures such as chitosan | |
| CA2691413C (en) | Reinforced composite implant | |
| CA2576422C (en) | Anti-adhesion barrier | |
| CN102630169B (en) | Composite layered hemostatic device | |
| JP7565214B2 (en) | Dissolution-resistant tissue-adhesive chitosan materials. | |
| CN101842122B (en) | Use of regenerative biofunctional collagen biomatrix for the treatment of visceral or parietal defects | |
| US20090004239A1 (en) | Dural repair material | |
| WO2013089493A1 (en) | Anti-adhesive composition, surgical mesh complex containing same for anti-adhesion functions, and method for manufacturing same | |
| ZA200605125B (en) | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan | |
| MXPA06007345A (en) | Wound d/ressing and method for controlling severe, life-threatening bleeding. | |
| AU2014258995A1 (en) | Fibrinogen-based tissue adhesive patches | |
| WO2012039367A1 (en) | Suture reinforcing material being for use in automatic suturing devices and containing hydrophilic polymer | |
| IL184044A (en) | Antimicrobial barriers including a chitosan biomaterial and methods for the manufacture thereof | |
| Ikada | Bioabsorbable fibers for medical use | |
| CN201286796Y (en) | Anti-adhesion hemostatic membrane with multilayer composite structure | |
| US7932429B2 (en) | Device designed for regenerating the human dermis and process for producing said device | |
| CN111035424A (en) | Interim device of closing abdomen | |
| JP4546772B2 (en) | Anti-adhesion material with release sheet | |
| AU2005244692A1 (en) | Tissue closing preparation | |
| Hu et al. | Gelatin sealing sheet for arterial hemostasis and anti-adhesion in vascular surgery: a dog model study | |
| CN212234959U (en) | A dressing device for the treatment of gastric ulcer under endoscope | |
| US11071805B2 (en) | Fibrinogen-based tissue adhesive patches | |
| KR101436615B1 (en) | Surgical mesh composite with anti-adhesion property and method for producing the same | |
| Carbon | Evaluation of biodegradable fleece-bound sealing: history, material science, and clinical application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140610 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140805 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150203 |